AzTrials
AzTrials

PeriodontitisNCT03919006

Netrin 1 and Its Receptor Unc5b as Markers of Periodontal Disease

A study testing non surgical periodontal treatment and Gingival crevicular fluid, saliva and serum collection in people with Periodontitis, run by Abant Izzet Baysal University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aimed to investigate gingival crevicular fluid (GCF), saliva and serum Netrin 1 and Unc5b levels in periodontal health and disease. A total of 60 individuals, 20 patients with periodontitis, 20 with gingivitis and 20 periodontally healthy individuals were included. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Periodontitis
What is being tested?
non surgical periodontal treatment and Gingival crevicular fluid, saliva and serum collection
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Jan 2018to 1 Apr 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Aged >18 years,
  • Having at least 16 natural teeth (excluding third molar),
  • Nonsmokers with no history of smoking,
  • Not having any diagnosed medical illness or drug intake that could affect the periodontal condition.

Who cannot join

  • Patients who had taken antibiotics, nonsteroidal antiinflammatory or any other drugs within the past 3 months,
  • Patients received nonsurgical or surgical periodontal treatment,
  • Patients who have a restorative and endodontic therapy requirement,
  • Having a removable partial denture and/or having orthodontic therapy,
  • Current pregnancy or lactation and having serum CRP > 3mg/L .

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Bolu Abant Izzet Baysal University

    Bolu, 14030

Other trials in Turkey (Türkiye)

About this study

Official title: Levels of Netrin 1 and Its Receptor Unc5b in Gingival Crevicular Fluid, Saliva and Serum in Periodontal Disease and Health

This study aimed to investigate gingival crevicular fluid (GCF), saliva and serum Netrin 1 and Unc5b levels in periodontal health and disease. A total of 60 individuals, 20 patients with periodontitis, 20 with gingivitis and 20 periodontally healthy individuals were included. Whole-mouth and site-specific clinical periodontal parameters including probing depth, clinical attachment level, bleeding on probing, gingival index, plaque index and papillar bleeding index were recorded. GCF, salivary and serum Netrin 1 and Unc5b levels were measured by enzyme-linked immunosorbent assay. Statistical analysis was performed by using non-parametric tests.

Read the detailed description

A total of 60 individuals, comprising 20 patients with Periodontitis (P Group), 20 patients with gingivitis (G Group), and 20 periodontally healthy controls (H Group) were involved in the study. The patients were diagnosed according to the new classification scheme. Stage and extent of periodontitis were also determined.

The clinical periodontal criteria for the diagnosis of the groups were as follows: the periodontitis group had interdental clinical attachment loss (CAL) ≥5 mm at site of greatest loss and periodontal probing depth (PD) ≥ 6 mm in one or more sites of the 2 non-adjacent teeth in at least two quadrants of the mouth. Accordingly, Stage III generalized periodontitis patients were included in the study. Patients were diagnosed as gingivitis with bleeding on probing ≥ 50 %, PD ≤3 mm, and no radiographic bone loss or CAL. Periodontally healthy individuals had no recorded history of periodontal problems, with PD ≤3 mm, no radiographic bone loss, good oral hygiene, no gingival inflammation.

Inclusion criteria were as follows: (1) aged >18 years, (2) having at least 16 natural teeth (excluding third molar),(3) nonsmokers with no history of smoking, (4) not having any diagnosed medical illness or drug intake that could affect the periodontal condition. The patients who had (1) taken antibiotics, nonsteroidal antiinflammatory or any other drugs within the past 3 months,(2) received nonsurgical or surgical periodontal treatment, (3) a restorative and endodontic therapy requirement, (4) a removable partial denture and/or having orthodontic therapy were excluded from the study. Current pregnancy or lactation and having serum C reactive protein (CRP) > 3mg/L were also the exclusion criteria.

All individuals were examined at baseline and four weeks after non-surgical periodontal treatment including, whole mouth probing depth (PD), CAL, presence of bleeding on probing (BOP), papillar bleeding index (PBI), gingival index (GI) and plaque index (PI) except the third molars. PD and CAL were measured at six sites per tooth using a manual periodontal probe.

The non-surgical periodontal treatment for periodontitis group included supra- and subgingival scaling, root planing and oral hygiene instructions. Subgingival scaling and root planing were performed under local anesthesia in two sessions within the 48-72 h. Gingivitis group had supra-and subgingival scaling, polishing and oral hygiene instructions. The treatment of gingivitis and periodontitis patients were performed by a periodontist (BM) using hand and ultrasonic instruments. All measurements were performed by the same calibrated examiner (SG).

Saliva sampling

Whole unstimulated saliva samples were collected. Each participant was asked first to rinse the mouth completely with tap water for 1 minutes, wait for 10 minutes, and then expectorate into sterile polypropylene tube for 5 minutes.

Gingival crevicular fluid (GCF) sampling

GCF samples were obtained from two nonadjacent interproximal sites in one single- rooted and one multi-rooted teeth by standardized filter paper strips. GCF was sampled from two sites with GI < 1, PD ≤ 3 mm and without BOP in the healthy group; two sites with GI ≥ 2, PD ≤ 3 mm and positive BOP (visible signs of inflammation) in the gingivitis group; and two deepest pocket (≥ 5 mm) with GI ≥ 2 and positive BOP in periodontitis group.

Serum sampling

Serum samples were taken following saliva and GCF sampling before the periodontal treatment. Six milliliters of venous blood were obtained by a standard venipuncture method and the serum was separated from blood by centrifugation at 1,500 g for 20 minutes.

Measurement of Netrin 1 and Unc5b levels in GCF, Saliva and Serum Samples

Netrin 1 and Unc5b levels in GCF, saliva and serum samples were measured by the enzyme-linked immunosorbent assay (ELISA) using commercial kits according to the manufacturer's guidelines.

Statistical Analysis

All data analyses were performed using a statistical software package. Comparisons of clinical and biochemical parameters between the study groups were performed using the Kruskal- Wallis with Mann Whitney U test with Bonferroni correction method. The intragroup comparisons (at baseline and first month) were performed using Wilcoxon test for paired samples. Associations among levels of the GCF, saliva and serum biomarkers and clinical parameters were also examined using the Spearman rank correlation analysis.

Conditions
Periodontitis
Being tested
non surgical periodontal treatment, Gingival crevicular fluid, saliva and serum collection
Keywords
periodontal diseases, cytokines, gingival crevicular fluid, saliva, serum
Medical subject headings
Periodontitis, Periodontal Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • non surgical periodontal treatmentOther

    SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.

  • Gingival crevicular fluid, saliva and serum collectionOther

    GCF with filter paper using the intracrevicular method, saliva and serum collection

Study groups in NCT03919006
Study groupRoleWhat they receive
PeriodontitisActive comparatorGCF, saliva and serum samples were taken before and after treatment from periodontitis patients. Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)
Receives: Other: non surgical periodontal treatment
GingivitisActive comparatorGCF, saliva and serum samples were taken before and after treatment from gingivitis patients. Intervention: Non- surgical periodontal treatment (Scaling and oral hygiene instructions)
Receives: Other: non surgical periodontal treatment
Periodontally healthyPlacebo comparatorGCF, saliva and serum samples were taken at baseline from periodontally healthy individuals.
Receives: Other: Gingival crevicular fluid, saliva and serum collection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Biochemical parameters (Netrin-1 and Unc5b)

    The changes in levels of Netrin-1 and Unc5b 4 weeks after periodontal treatment determined by ELISA.

    The changes in levels of Netrin-1 and Unc5b were analyzed to determine as a diagnostic biomarker of periodontal disease.

    Measured: Baseline and 4 weeks after treatment

Secondary outcomes (6)
  1. Probing pocket depth

    The changes in probing pocket depth was measured for determining severity of disease and clinical outcome

    Measured: Baseline and 4 weeks after treatment

  2. Clinical attachment loss

    The changes in probing pocket depth was measured for determining severity of disease

    Measured: Baseline and 4 weeks after treatment

  3. Gingival index

    Gingival index was recorded for classifying and evaluating sulcular gingival inflammation. Gingival index was also analyzed to detect the relationship between Netrin-1 and Unc5b.

    Measured: Baseline and 4 weeks after treatment

  4. Plaque index

    Plaque index was recorded for determining and classifying oral hygiene status

    Measured: Baseline and 4 weeks after treatment

  5. Bleeding on probing

    Bleeding on probing was recorded for classifying and evaluating gingival inflammation especially for apically sulcular inflammation. This was also analyzed to detect the relationship between Netrin-1 and Unc5b.

    Measured: Baseline and 4 weeks after treatment

  6. Papillar bleeding index

    Papillar bleeding index was recorded for classifying and evaluating the papillar gingival inflammation. This index was also analyzed to detect the relationship between Netrin-1 and Unc5b.

    Measured: Baseline and 4 weeks after treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Apr 2019
  2. Study start1 Jan 2018
  3. Primary completion1 Feb 2019
  4. Study completion1 Apr 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
Parallel Assignment
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03919006
Sponsor's protocol ID
2017/87
Other IDs
2018.06.05.1269
Status last verified
Apr 2019
First submitted
15 Apr 2019
Last updated
18 Apr 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, Flemmig TF, Garcia R, Giannobile WV, Graziani F, Greenwell H, Herrera D, Kao RT, Kebschull M, Kinane DF, Kirkwood KL, Kocher T, Kornman KS, Kumar PS, Loos BG, Machtei E, Meng H, Mombelli A, Needleman I, Offenbacher S, Seymour GJ, Teles R, Tonetti MS. Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018 Jun;89 Suppl 1:S173-S182. doi: 10.1002/JPER.17-0721.

    PubMed 29926951
  • Caton JG, Armitage G, Berglundh T, Chapple ILC, Jepsen S, Kornman KS, Mealey BL, Papapanou PN, Sanz M, Tonetti MS. A new classification scheme for periodontal and peri-implant diseases and conditions - Introduction and key changes from the 1999 classification. J Clin Periodontol. 2018 Jun;45 Suppl 20:S1-S8. doi: 10.1111/jcpe.12935.

    PubMed 29926489

Questions about this trial

What is this clinical trial studying?

A study testing non surgical periodontal treatment and Gingival crevicular fluid, saliva and serum collection in people with Periodontitis, run by Abant Izzet Baysal University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Biochemical parameters (Netrin-1 and Unc5b) (time frame: Baseline and 4 weeks after treatment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03919006, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Apr 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT03919006 | AzTrials